Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alector Inc.
This is a phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 administered intravenously in participants with Early Alzheimer's Disease.
Age
50–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Early AD including evidence of brain amyloidosis by CSF or PET
MMSE score ≥ 20 points, CDR Global Score of 0.5 - 1.0, and RBANS score on the DMI ≤95.
Study partner who consents to study participation and who cares for/visits the participant at least 10 hours a week
Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).
You may not be if
Dementia due to a condition other than AD including, but not limited to, FTD, Parkinson's disease, dementia with Lewy bodies, Huntington disease, or vascular dementia.
Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
Current uncontrolled hypertension, diabetes mellitus or thyroid disease. Clinically significant heart disease, liver disease or kidney disease.
History or evidence of clinically significant brain disease other than AD.
Females who are pregnant or breastfeeding, or planning to conceive within the study period.
Any experimental vaccine or gene therapy.
History of unresolved cancer.
Current use of anticoagulant medications.
Residence in a skilled nursing facility, convalescent home, or long term care facility at screening; or requires continuous nursing care.
Participant is positive for presence of APOE e4/e4 genotype.
Clareo Health | A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
